BREED: Generating novel inhibitors through hybridization of known ligands. Application to CDK2, P38, and HIV protease

Journal of Medicinal Chemistry

Volumn 47, Issue 11, 2004, Pages 2768-2775

  Pierce, Albert C ^a   Rao, Govinda ^a   Bemis, Guy W ^a  

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; LIGAND; PROTEIN; PROTEINASE INHIBITOR; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

ARTICLE; AUTOMATION; CHEMICAL BOND; CHEMICAL STRUCTURE; COMBINATORIAL CHEMISTRY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HIGH THROUGHPUT SCREENING; HYBRIDIZATION; PROTEIN TARGETING;

CRYSTALLIZATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; ENZYME INHIBITORS; HIV PROTEASE; HIV PROTEASE INHIBITORS; LIGANDS; MITOGEN-ACTIVATED PROTEIN KINASES; MODELS, MOLECULAR; MOLECULAR STRUCTURE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 2442647742     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030543u     Document Type: Article

References (36)

1. Ho, C. M. W.; Marshall, G. R. SPLICE: A program to assemble partial query solutions from three-dimensional database searches into novel ligands. J. Comput.-Aided Mol. Des. 1993, 7, 623-647.
2. Schmitt, S.; Kuhn, D.; Klebe, G. A New Method to Detect Related Function Among Proteins Independent of Sequence and Fold Homology. J. Mol. Biol. 2002, 323, 387-406.
3. Chen, Z.; Li, Y.; Chen, E.; Hall, D. L.; Darke, P. L. et al. Crystal structure at 1.9-A resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bioavailable inhibitor of the HIV proteases. J. Biol. Chem. 1994, 269, 26344-26348.
4. Dalby, A.; Nourse, J. G.; Hounshell, W. D.; Gushurst, A. K. I.; Grier, D. L. et al. Description of Several Chemical Structure File Formats Used by Computer Programs Developed at Molecular Design Limited. J. Chem. Inf. Comput. Sci. 1992, 32, 244-255.
5. Weininger, D. SMILES 1. Introduction and Encoding Rules. J. Chem. Inf Comput. Sci. 1988, 28, 31-36.
6. Kim, E. E.; Baker, C. T.; Dwyer, M. D.; Murcko, M. A.; Rao, B. G. et al. Crystal-strucure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme. J. Am. Chem. Soc. 1995, 117, 1181-1182.
7. Vazquez, M. L.; Bryant, M. L.; Clare, M.; DeCrescenzo, G. A.; Doherty, E. M. et al. Inhibitors of HIV-1 Protease Containing the Novel and Potent (R)-Hydroxyethyl)sulfonamide Isostere. J. Med. Chem. 1995, 38, 581-584.
8. Krohn, A.; Redshaw, S.; Ritchie, J. C.; Graves, B. J.; Hatada, M. H. Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere. J. Med. Chem. 1991, 34, 3340-3342.
9. Martin, J. L.; Begun, J.; Schindeler, A.; Wickramasinghe, W. A.; Alewood, D. et al. Molecular recognition of macrocyclic peptidomimetic inhibitors by HIV-1 protease. Biochemistry 1999, 38, 7978-7988.
10. Priestle, J. P.; Fassler, A.; Rosel, J.; Tintelnot-Blomley, M.; Strop, P. et al. Comparative analysis of the X-ray structures of HIV-1 and HIV-2 proteases in complex with CGP 53820, a novel pseudosymmetric inhibitor. Structure 1995, 3, 381-389.
11. Dohnalek, J.; Hasek, J.; Duskova, J.; Petrokova, H.; Hradilek, M. et al. Hydroxyethylamine isostere of an HIV-1 protease inhibitor prefers its amine to the hydroxy group in binding to catalytic aspartates. A synchrotron study of HIV-1 protease in complex with a peptidomimetic inhibitor. J. Med. Chem. 2002, 45, 1432-1438.
12. Kaldor, S. W.; Kalish, V. J.; 2nd, J. F. D.; Shetty, B. V.; Fritz, J. E. et al. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J. Med. Chem. 1997, 40, 3979-3985.
13. Bone, R.; Vacca, J. P.; Anderson, P. S.; Holloway, M. K. X-ray crystal structure of the HIV protease complex with L-700,417, an inhibitor with pseudo C2 symmetry. J. Am. Chem. Soc. 1991, 113, 9382-9384.
14. Wang, Z.; Canagarajah, B. J.; Boehm, J. C.; Kassisa, S.; Cobb, M. H. et al. Structural basis of inhibitor selectivity in MAP kinases. Structure 1998, 6, 1117-1128.
15. Shewchuk, L.; Hassell, A.; Wisely, B.; Rocque, W.; Holmes, W. et al. Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase. J. Med. Chem. 2000, 43, 133-138.
16. Clare, P. M.; Poorman, R. A.; Kelley, L. C.; Watenpaugh, K. D.; Bannow, C. A. et al. The cyclin-dependent kinases cdk2 and cdk5 act by a random, anticooperative kinetic mechanism. J. Biol. Chem. 2001, 276, 48292-48299.
17. Ghosh, A. K.; Thompson, W. J.; Lee, H. Y.; McKee, S. P.; Munson, P. M. et al. Cyclic Sulfolanes as Novel and High Affinity P2 Ligands for HIV-1 Protease Inhibitors. J. Med. Chem. 1993, 36, 924-927.
18. Kempf, D. J.; Norbeck, D. W.; Codacovi, L.; Wang, X. C.; Kohlbrenner, W. E. et al. Structure-Based, C2 Symmetric Inhibitors of HIV Protease. J. Med. Chem. 1990, 33, 2687-2689.
19. Patel, D. V.; Rielly-Gauvin, K.; Ryono, D. E.; Free, C. A.; Smith, S. A. et al. Activated Ketone Based Inhibitors of Human Renin. J. Med. Chem. 1993, 36, 2431-2447.
20. Lauri, G.; Bartlett, P. A. CAVEAT: a program to facilitate the design of organic molecules. J. Comput.-Aided Mol. Des. 1994, 8, 51-66.
21. Ghosh, A. K.; Thompson, W. J.; McKee, S. P.; Duong, T. T.; Lyle, T. A. et al. 3-Tetrahydrofuran and Pyran Urethanes as High-Affinity P2-Ligands for HIV-1 Protease Inhibitors. J. Med. Chem. 1993, 36, 292-294.
22. Adams, J. L.; Lee, D.; Long, S. A. Novel aryloxy substituted pyrimidine imidazole compounds. WO9857966, 1998.
23. Pease, E. J.; Breault, G. A.; Morris, J. J. Preparation of pyrimidin-2-amines as cyclin-dependent serine/threonine kinase (CDK) inhibitors. WO0164654, 2001.
24. Pease, E. J.; Breault, G. A.; Williams, E. J.; Bradbury, R. H.; Morris, J. J. Preparation of 2,4-di(hetero)arylamino(oxy)-5-substituted pyrimidines as antineoplastic agents. WO0164655, 2001.
25. Nuss, J. M.; Harrison, S. D.; Ring, D. B.; Boyce, R. S.; Johnson, K. et al. Preparation of aminopyrimidines and -pyridines as glycogen synthase kinase 3 inhibitors. WO0220495, 2002.
26. Armistead, D. M.; Bemis, J. E.; Pietro, L. V. D.; Geuns-Meyer, S. D.; Habgood, G. J. et al. Preparation of arylaminopyrimidines as Kinase inhibitors. WO0160816, 2001.
27. Thomas, A. P. Preparation of 4,6-dianilinopyrimidines derivatives as tyrosine kinase inhibitors. WO9515952, 1995.
28. Breault, G. A.; Jewsbury, P. J.; Pease, J. E. Preparation of bis-(anilino)pyrimidines as CDK inhibitors. WO0012486, 2000.
29. Cumming, J. G. Preparation of 4-anilinopyrimidines as p38 kinase inhibitors. WO0127089, 2001.
30. Stahl, M.; Rarey, M. Detailed Analysis of Scoring Functions for Virtual Screening. J. Med. Chem. 2001, 44, 1035-1042.
31. Walters, W. P.; Murcko, M. A. Prediction of 'drug-likeness'. Adv. Drug Deliv. Rev. 2002, 54, 255-271.
32. Jorgensen, W. L.; Duffy, E. M. Prediction of drug solubility from structure. Adv. Drug Deliv. Rev. 2002, 54, 355-366.
33. Egan, W. J.; Lauri, G. Prediction of intestinal permeability. Adv. Drug Deliv. Rev. 2002, 54, 273-289.
34. Ekins, S.; Boulanger, B.; Swaan, P. W.; Hupcey, M. A. Towards a new age of virtual ADME/TOX and multidimensional drug discovery. J. Comput.-Aided Mol. Des. 2002, 16, 381-401.
35. Pegg, S. C.-H.; Haresco, J. J.; Kuntz, I. D. A genetic algorithm for structure-based de novo design. J. Comput.-Aided Mol. Des. 2001, 15, 911-933.
36. Pearlman, D. A.; Murcko, M. A. CONCERTS: Dynamic Connection of Fragments as an Approach to de Novo Ligand Design. J. Med. Chem. 1996, 39, 1651-1663.